Abstract:Hepatitis E, which is caused by infection with hepatitis E virus (HEV), is a global health problem in both developed and developing countries. An efficacious hepatitis E vaccine was licensed (by China) in 2011 with a trade name of Hecolin. The antigen contained in this vaccine is a truncated version of the sole capsid protein encoded by open reading frame 2, which is designated p239. In this study, the real-time and real-condition stability and accelerated stability of five lots of hepatitis E vaccine products at the end of the designated shelf life, were assessed by a well-established quality analysis platform. The protein integrity of p239 that was recovered from the vaccine lots was demonstrated using CE-SDS, LC-MS and MALDI-TOF MS. The particle characteristics of the recovered vaccine antigen were assessed by TEM and HPSEC. The immunogenicity of hepatitis E vaccines was assessed by a mouse potency assay, which is part of product release and stability testing. Several methods were employed to assess the antigenicity of vaccines with or without adjuvant dissolution. Specifically, the well-established methods of sandwich ELISA and surface plasma resonance (SPR)-based BIAcore were used with unique murine monoclonal antibodies. Most interesting, two 'dissolution-free' immunoassays were also used for in situ antigenicity assessment of the vaccines. In addition to the confirmation of vaccine stability at the end of expiry dating, i.e., after storage in recommended conditions (2-8 degrees C) for 36 months, the mouse potency assay and sandwich ELISA were used to assess the accelerated stability of prefilled syringes to demonstrate the feasibility of out-of-cold chain storage. In summary, molecular and functional characterization confirmed the shelf life stability of the vaccine at the end of expiry dating and the feasibility of transporting the hepatitis E vaccine for a given period of time out of cold chains. (C) 2019 Elsevier B.V. All rights reserved.

A Study on Biodegradable PLGA Microspheres as A Delivery System for Recombinant Vaccine against Hepatitis E

Alginate–Chitosan–PLGA Composite Microspheres Enabling Single-Shot Hepatitis B Vaccination

Dissolving Microneedle Arrays As a Hepatitis B Vaccine Delivery System Adjuvanted by APC-Targeted Poly (Lactic-Co-glycolic Acid) (PLGA) Nanoparticles

Research on Biodegradable Microspheres as HPV-E7 Protein Adjuvant

Preparation of Oral Vaccine Microspheres for Newcastle Disease Virus

Pharmaceutical and Immunological Evaluation of A Single-Dose Hepatitis B Vaccine Using Plga Microspheres

Preparation and Immune Effect of HEV ORF2 P206@PLGA Nanoparticles

[Immunogenicity of Single-Dose HBsAg-PLGA Controlled Release Microspheres in Mice].

[Preparation, Release and Immunogenicity Evaluation of HBsAg-PLGA Microspheres].

Poly-DL-lactide-poly(ethylene glycol) microspheres as oral and parenteral delivery systems for hepatitis B surface antigen

[Fermentation, Purification and Immunogenicity Evaluation of Hepatitis E Virus-Like Particles Expressed in Hansenula Polymorpha].

[The Immuno-Protect Study of a Hepatitis E Virus ORF2 Peptide Expressed in E. Coli].

Development of PLGA-PEG-PLGA Hydrogel Delivery System for Enhanced Immunoreaction and Efficacy of Newcastle Disease Virus DNA Vaccine

Demonstration of Real-Time and Accelerated Stability of Hepatitis E Vaccine with a Combination of Different Physicochemical and Immunochemical Methods.

Controlled Release of PEI/DNA Complexes from PLGA Microspheres As a Potent Delivery System to Enhance Immune Response to HIV Vaccine DNA Prime/mva Boost Regime.

Effi cacy and safety of a recombinant hepatitis E vaccine in healthy adults : a large-scale , randomised , double-blind placebo-controlled , phase 3 trial

A Phase 1 Randomized Open-Label Clinical Study To Evaluate The Safety Crossmark And Tolerability Of A Novel Recombinant Hepatitis E Vaccine

A Bacterially Expressed Particulate Hepatitis E Vaccine: Antigenicity, Immunogenicity and Protectivity on Primates

Mannose-Modified PLGA Nanoparticles for Sustained and Targeted Delivery in Hepatitis B Virus Immunoprophylaxis

Construction of an Effective Delivery System for DNA Vaccines Using Biodegradable Polylactic Acid Based Microspheres.

Hepatitis C Virus E2 Protein Encapsulation into Poly D, L-Lactic-co-glycolide Microspheres Could Induce Mice Cytotoxic T-cell Response.